Nuvation Bio Inc (NUVB) concluded trading on Wednesday at a closing price of $2.56, with 7.1 million shares of worth about $18.19 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -0.78% during that period and on July 23, 2025 the price saw a gain of about 8.94%. Currently the company’s common shares owned by public are about 338.84M shares, out of which, 226.12M shares are available for trading.
Stock saw a price change of 14.80% in past 5 days and over the past one month there was a price change of 26.11%. Year-to-date (YTD), NUVB shares are showing a performance of -14.67% which decreased to -3.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.54 but also hit the highest price of $3.97 during that period. The average intraday trading volume for Nuvation Bio Inc shares is 5.86 million. The stock is currently trading 18.74% above its 20-day simple moving average (SMA20), while that difference is up 18.09% for SMA50 and it goes to 10.97% higher than SMA200.
Nuvation Bio Inc (NYSE: NUVB) currently have 338.84M outstanding shares and institutions hold larger chunk of about 48.57% of that.
The stock has a current market capitalization of $871.08M and its 3Y-monthly beta is at 1.34. It has posted earnings per share of -$2.34 in the same period. It has Quick Ratio of 9.01 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NUVB, volatility over the week remained 6.47% while standing at 7.15% over the month.
Stock’s fiscal year EPS is expected to rise by 69.19% while it is estimated to increase by 8.57% in next year. EPS is likely to grow at an annualized rate of 38.04% for next 5-years, compared to annual growth of -49.14% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citizens JMP on April 23, 2025 offering a Mkt outperform rating for the stock and assigned a target price of $6 to it. Coverage by Jefferies stated Nuvation Bio Inc (NUVB) stock as a Buy in their note to investors on March 27, 2024, suggesting a price target of $10 for the stock. On March 26, 2024, BTIG Research Upgrade their recommendations, while on January 06, 2023, Jefferies Downgrade their ratings for the stock with a price target of $2. Stock get a Neutral rating from BTIG Research on August 02, 2022.
